Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H25N3O4.CH4O3S |
Molecular Weight | 491.557 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.COC1=CC2=C(CN(CC2)C3=CC(N)=C4C=C(OC)C(OC)=CC4=N3)C=C1OC
InChI
InChIKey=FMDPOTBKJNHQLC-UHFFFAOYSA-N
InChI=1S/C22H25N3O4.CH4O3S/c1-26-18-7-13-5-6-25(12-14(13)8-19(18)27-2)22-10-16(23)15-9-20(28-3)21(29-4)11-17(15)24-22;1-5(2,3)4/h7-11H,5-6,12H2,1-4H3,(H2,23,24);1H3,(H,2,3,4)
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10845763
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10845763
Abanoquil (UK-52,046), an antiarrhythmic drug, is an alpha 1-adrenoceptor antagonist, has been studied for the treatment of erectile dysfunction.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094251 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10845763 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1349492
single oral doses of abanoquil 0.25, 0.5 and 1 mg
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID40922813
Created by
admin on Sat Dec 16 09:55:49 GMT 2023 , Edited by admin on Sat Dec 16 09:55:49 GMT 2023
|
PRIMARY | |||
|
MAX6HQS78D
Created by
admin on Sat Dec 16 09:55:49 GMT 2023 , Edited by admin on Sat Dec 16 09:55:49 GMT 2023
|
PRIMARY | |||
|
164088
Created by
admin on Sat Dec 16 09:55:49 GMT 2023 , Edited by admin on Sat Dec 16 09:55:49 GMT 2023
|
PRIMARY | |||
|
118931-00-3
Created by
admin on Sat Dec 16 09:55:49 GMT 2023 , Edited by admin on Sat Dec 16 09:55:49 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD